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Introduction {#sec1}
============

Treatment of chronic viral diseases by direct inhibition of viral targets frequently leads to rapid development of virally encoded resistance. Therapies targeted to host proteins involved in the viral life cycle offer an opportunity to both raise the barrier to generation of resistance and generate antivirals able to treat a broad range of viral diseases. However, this has been hindered in the past by the relative rarity of targets essential to the virus but nonessential to the host, and the inherent complexity of discovering and developing drugs that effectively target these proteins.

From the 1940s to 2007, 73% of the 155 small molecules approved as anticancer drugs were of natural origin, either directly or derived ([@bib35]). As opposed to this, few natural products (NPs) had been approved for use in antiviral therapy, although they were the inspiration for antiviral nucleoside analogs ([@bib8]).

Many bacterial NPs, including the well-described polyketide class, have been shown to bind to and inhibit mammalian cellular proteins, including viral host-encoded targets such as cyclophilins, v-ATPases ([@bib19]), CRM1 ([@bib43]), and Hsp90 ([@bib32]). They can be produced at low cost of goods by fermentation, and frequently the lead compound has both excellent potency against the target and good cellular penetration. However, NPs often display polypharmacology and have less than optimal mammalian pharmacokinetics and physicochemical properties.

The tools available for optimizing NPs are ever increasing. Specifically, bioengineering has been proposed as a way to reinvigorate NP drug discovery ([@bib20], [@bib50]). In the past, semisynthetic approaches have been the most frequently used route to improve the drug-like properties of an NP hit. However, the available semisynthetic options are predetermined by the array of functional groups on the NP. In contrast, bioengineering options are predetermined by the biosynthetic pathway. The potential changes are thus orthogonal to those available to semisynthesis.

Whole-genome sequencing is now straightforward and easily affordable, and for NP classes such as the modular polyketide synthases (PKSs), knowledge of the DNA sequence encoding the biosynthetic gene cluster enables rapid understanding of gene product function. When combined with improved techniques for DNA transfer and the rapid targeted alteration of biosynthetic genes, this provides a powerful platform for focused drug discovery efforts with the aim of improving drug-like properties and pharmacokinetics and reducing off-target effects. These bioengineering techniques are readily combined with semisynthesis to identify molecules with further improved properties. In particular, inactivation of precursor pathways can allow mutasynthesis, the process of feeding a synthetic analog of the precursor which is then incorporated, biosynthetically, into the final molecule ([@bib17], [@bib27]). This enables a combinatorial element in bioengineering.

Cyclophilins are a class of peptidyl-prolyl isomerases, proteins that catalyze the *cis-trans* isomerization of the peptide bond preceding prolyl residues. Knockout studies in several species, including mice and human cells, confirm that they have limited or no effect on cellular growth and survival ([@bib31], [@bib13], [@bib11], [@bib9]). However, cyclophilins recruited from host cells have been shown to have essential roles in many viral life cycles. Initially, cyclophilin A was shown to be incorporated into HIV-1 virions ([@bib48], [@bib15]) involved in viral replication, its expression level in patients being related to the speed of progression to AIDS ([@bib2]). Isomerase activity of cyclophilin A, and potentially others such as cyclophilin B and cyclophilin 40, have been shown to be required for hepatitis C virus (HCV) replication ([@bib7], [@bib53], [@bib25]). Other viruses in which cyclophilin involvement has been implicated in their life cycle or cyclophilin inhibitors have shown inhibitory activity include vaccinia virus ([@bib10]), West Nile virus, Dengue virus, yellow fever virus ([@bib40]), hepatitis B virus (HBV) ([@bib39]), human papilloma virus ([@bib4]), cytomegalovirus (CMV) ([@bib26]), SARS coronavirus ([@bib38]), Japanese encephalitis virus ([@bib22]), and influenza A ([@bib30]).

We now describe the use of combined bioengineering and semisynthetic approaches to optimize the drug-like properties of sanglifehrin A, an NP cyclophilin inhibitor, to generate NVP018 (formerly BC556). Preclinical analysis reveals NVP018 to be a molecule displaying in vitro inhibition of HBV and HCV and potent in vitro and oral in vivo inhibition of HIV-1.

Results {#sec2}
=======

Bioengineering and Mutasynthesis of *Streptomyces* sp. A92-308110 {#sec2.1}
-----------------------------------------------------------------

Previous semisynthetic derivatization to replace the spirolactam fragment of sanglifehrin A led to generation of the sangamides, molecules with improved solubility, potency, and selectivity ([@bib33]). This approach moved the immunosuppressive NPs from tool compounds appropriate for chemical genetics to being compounds that could reasonably be pursued as therapeutic agents. We then used bioengineering to make further alterations to the macrocyclic portion of the molecule, changes that could not have otherwise been done without complex total synthesis. The major aim of this work was to further improve the drug-like properties of the final molecule by specific manipulation of the parts of the molecule involved in cyclophilin binding.

The gene cluster required for biosynthesis of sanglifehrin A has been published ([@bib41]). Generation of the sanglifehrins requires 13 typical PKS extension modules and three nonribosomal peptide synthetase (NRPS) modules incorporating [l]{.smallcaps}-valine, *meta*-[l]{.smallcaps}-tyrosine, and [l]{.smallcaps}-piperazic acid. In addition, a crotonyl-CoA reductase/carboxylase (CCR) is present for generation of the PKS starter unit (2*E*)-2-ethylmalonyl-CoA, an iterative type I PKS is required for the supply of the unique (2*S*)-2-(2-oxo-butyl)malonyl-CoA extender unit, and a phenylalanine hydroxylase produces the NRPS extender unit *meta*-[l]{.smallcaps}-tyrosine from [l]{.smallcaps}-phenylalanine.

Analysis of the published crystal structures of sanglifehrin A ([@bib21]) and an analog with the spirolactam fragment removed ([@bib44]) suggested that manipulation of the electronics on the *meta*-[l]{.smallcaps}-tyrosine moiety might lead to improved binding to cyclophilins. To achieve this, we inactivated *sfaA*, the gene encoding the phenylalanine hydroxylase responsible for *meta-* [l]{.smallcaps}-tyrosine biosynthesis. Deletion of *sfaA* was carried out by homologous recombination, following conjugation of a plasmid containing the appropriate deletion construct into *Streptomyces* sp. A92-308110 using standard techniques ([@bib28]), and led to the strain BIOT-4585. Due to the lack of *meta-* [l]{.smallcaps}-tyrosine production, BIOT-4585 did not produce sanglifehrin A unless fed with *meta-* [l]{.smallcaps}-tyrosine or an analog.

Synthesis and Selection of NVP018 {#sec2.2}
---------------------------------

A screen was then carried out by feeding a selection of appropriate *meta-* [l]{.smallcaps}-tyrosine analogs to BIOT-4585 to determine its ability to generate sanglifehrin analogs (see [Figure 1](#fig1){ref-type="fig"} ). Fermentations with those analogs successfully accepted as substrates were scaled up to allow isolation of new sanglifehrins. The antiviral activity and ADME (absorption, distribution, metabolism, excretion) properties of each analog were analyzed, and the best of the analogs were subjected to semisynthesis to yield the corresponding sangamides as described previously ([@bib33]). The resulting sangamides were again analyzed for antiviral activity and ADME properties, and from this NVP018 was chosen as a potential drug candidate (data not shown). NVP018 is derived from a sanglifehrin resulting from incorporation of 5-fluoro-*meta-* [l]{.smallcaps}-tyrosine. Semisynthesis replaced the spirolactam-containing portion of the sanglifehrin with a tertiary hydroxamic amide moiety ([Table S1](#app2){ref-type="sec"}). Of the sangamides tested, NVP018 had the best combination of properties ([Table 1](#tbl1){ref-type="table"} ), including more potent inhibition of CypA PPIase activity and inhibition of HCV replicons.Figure 1Overview of Biosynthetic Medicinal Chemistry Route to Generate BC544 and NVP018.Table 1Comparison of Cyclophilin Inhibition, HCV NS5A-Cyclophilin A Complex Disruption, and Genotype 1b Replicon Inhibition for Cyclosporin and Sanglifehrin AnalogsCypA PPIase IC~50~ (nM)NS5A-CypA disruption IC~50~ (μM)HCV Huh5.2 Gt1b replicon EC~50~ (nM)HCV Gt1b replicon CC~50~ (μM)CsA9.7 ± 1.300.98 ± 0.08306 ± 1414.4Alisporivir0.8 ± 0.050.24 ± 0.0296 ± 2311.2BC5442.7 ± 0.20.36 ± 0.03125 ± 22\>100NVP0180.3 ± 0.030.10 ± 0.0133 ± 10\>100

NVP018 Has Reduced Off-Target Inhibition of Drug Transporters {#sec2.3}
-------------------------------------------------------------

One of the issues with cyclosporin-based cyclophilin inhibitors is off-target inhibition of transporter proteins. Alisporivir, for example, inhibits multiple transporter proteins, including OATP1B1, OATP1B3, and MRP2, which are involved in bilirubin transport. It is this inhibition which is now thought to be the mechanism for the dose-limiting hyperbilirubinemia ([@bib3]). These compounds also have drug-drug interaction concerns through inhibition of xenobiotic transporters such as Pgp and BSEP ([@bib23], [@bib51]). Comparison of the inhibition of these transporters using vesicular transport or uptake transporter inhibition assays, and in vitro inhibition of the xenobiotic transporters Pgp and BSEP revealed that while alisporivir (ALV) and cyclosporin A (CsA) potently inhibited many of them, BC544 ([Figure 1](#fig1){ref-type="fig"}, previously stated as compound 3o in [@bib33]) and NVP018 showed minimal or no inhibition (see [Table 2](#tbl2){ref-type="table"} ). To test the effect of NVP018 on bilirubin levels, we then dosed three mice with up to 250 mg/kg/day NVP018 for 7 days. In all cases, almost no increase was seen in either bilirubin or liver enzymes when measured at the end of the study (see [Table S2](#app2){ref-type="sec"}).Table 2Comparison of Solubility, Plasma Protein Binding, and Transporter InhibitionSolubility in PBS pH 7.4 (μM)Human plasma protein binding (fraction unbound) (%)OATP1B1 IC~50~ (μM)OATP1B3 IC~50~ (μM)MRP2 IC~50~ (μM)Pgp IC~50~ (μM)BSEP IC~50~ (μM)CsA36\<10.850.134.10.730.46Alisporivir15\<40.450.19∼16 (\>49%)0.720.18BC5443302810.975.40\>50\>5029.3NVP018140224.311.75\>50\>5012.3

NVP018 Displays In Vivo Pharmacokinetics Suitable for Once-Daily Dosing {#sec2.4}
-----------------------------------------------------------------------

To confirm bioavailability following oral dosing, a single oral dose of 5 mg/kg was given to groups of mice, rats, and dogs. In all cases, blood concentrations were maintained above the HCV EC~90~ for 24--48 hr post dose ([Figure 2](#fig2){ref-type="fig"} ). Liver levels were found to be 3- to 6-fold higher than blood levels, and up to 230-fold higher than plasma levels, revealing further concentration within the target organ for treatment of hepatic disease (see [Table S3](#app2){ref-type="sec"}). Analysis of other organs in rats, including brain, heart, and lungs, revealed much lower exposure following oral dosing compared with the blood and liver, probably because of first-pass extraction by the liver.Figure 2Mean Blood Concentration-Time Profiles of NVP018 Following a Single Oral Dose of 5 mg/kg to CD-1 Mice, SD Rats, or Beagle DogsValues represent the average concentrations calculated in groups of 3 mice with standard deviation shown with error bars.

NVP018 Is an Inhibitor of HCV Replication In Vitro {#sec2.5}
--------------------------------------------------

Until recently the standard-of-care treatment for chronic HCV infection has been a combination of interferon and ribavirin for 6--12 months. Use of recently approved drugs with high barrier to resistance, such as the nucleotide polymerase inhibitor (NPI) sofosbuvir, leads to high levels of viral clearance (AASLD 2011, abstract; [@bib47]). Cyclophilin inhibition is one of the few mechanisms of action of HCV inhibition that consistently shows a high barrier to resistance, and in phase 2 trials some patients were clear of the virus after being treated for 24 weeks with 1000 mg/day ALV monotherapy ([@bib37]). Alisporivir, a nonimmunosuppressive semisynthetic derivative of CsA, is a potent cyclophilin inhibitor which was in phase 3 trials for the treatment of HCV infection. NVP018 could provide a suitable alternative backbone for use in an interferon-free combination. Comparison of the inhibitory potential of NVP018 with the semisynthetic sangamide, BC544, and ALV against HCV replicons revealed that NVP018 was much more potent in all assays, and was similarly active against all genotypes tested (see [Table 3](#tbl3){ref-type="table"} ). Analysis of the effect of increasing levels of either human serum or fetal calf serum (FCS) also confirmed that there was no effect on antiviral potency with addition of up to 40% serum (see [Table S4](#app2){ref-type="sec"}).Table 3EC~50~ of Cross Genotype HCV Replicon Inhibition and IC~50~ of HIV-1 and HBV InhibitionHCVHIV-1HBVHCV Huh7 Gt1a replicon EC~50~ (nM)HCV Huh7 Gt1b replicon EC~50~ (nM)HCV Huh7 Gt2a replicon EC~50~ (nM)HIV-1 HeLa cells IC~50~ (nM)HBV Huh7 stable HBV DNA IC~50~ (nM)HBV Huh7 stable HBsAg IC~50~ (nM)HBV Huh7 stable HBeAg IC~50~ (nM)HBV HepG2 transfected HBsAg T/C day 3 at 2 μM (%)CsA198 ± 13137 ± 4455 ± 375300NANANANAAlisporivir98 ± 1176 ± 5102 ± 81500 ± 240\>10,000\>10,000\>10,00018BC54463 ± 458 ± 589 ± 6310 ± 206106002809.6NVP01818 ± 213 ± 121 ± 3130 ± 159505203508.8[^1]

To compare the barrier to resistance of NVP018 in HCV, Huh7-Con1 cells were serially passaged for 7 weeks in the presence of 300 μg/ml G418 and increasing concentrations of NVP018 or ALV. Colonies were amplified, and cellular RNA extracted and analyzed by quantitative RT-PCR. For all ALV-resistant replicons, only the previously described and clinically relevant D320E mutation was consistently found in all clones analyzed. In the case of NVP018-resistant replicons, all clones analyzed contained the same five mutations: L27I, R318W, D320E, S370P, and C446S. When NVP018 was tested against separate replicons containing individual mutations from this list, only the D320E mutation was shown to confer more than 2-fold resistance alone. The combination of all five mutations only led to ∼4-fold resistance compared with the wild-type.

NVP018 Is an Inhibitor of HBV Replication In Vitro {#sec2.6}
--------------------------------------------------

There have been previous reports that cyclophilin inhibitors such as CsA have an inhibitory effect on HBV replication ([@bib52]). We therefore tested NVP018 in two in vitro models to look for inhibitory activity. The first involved transfecting Huh7 cells with HBV DNA (8 μg) in the presence of 2 μM NVP018, ALV, or DMSO. After days 0, 1, 2, and 3, amounts of de novo HBV proteins HBsAg and HBeAg present in cell extracts or supernatants were quantified by ELISA, in triplicate. Data shown in [Table 3](#tbl3){ref-type="table"} revealed that NVP018 and ALV potently inhibited HBV replication at this concentration. An additional assay was run using HepG2 cells stably expressing replicating HBV. These were treated with DMSO, NVP018, or ALV at three concentrations (0.1, 1, and 10 μM). The effect on HBV replication was monitored by treating HepG2 cells with test article at the relevant concentration for 3 days, removing the supernatant, retreating and analyzing after an additional 48 and 72 hr by HBsAg ELISA, HBeAg ELISA, and for HBV DNA, in triplicate, in both cell extracts and supernatants. This assay confirmed a dose-dependent effect of NVP018 against HBV replication at the final time point.

NVP018 Is an Inhibitor of HIV-1 Replication In Vitro {#sec2.7}
----------------------------------------------------

Although no cyclophilin inhibitors are currently in clinical development for treatment of HIV-1 infection, ALV was originally developed as an inhibitor of HIV-1 replication, and showed a mean ∼1 log drop in viral load following 14 days of dosing in HIV/HCV-coinfected patients ([@bib14]). We therefore tested NVP018 in comparison with BC544 and ALV in a CD4+ HeLa HIV-1 inhibitory fluorescence-activated cell sorting (FACS) assay to see if improvements in inhibition of in vitro HCV replicons carried through to HIV-1 inhibitory assays. NVP018 was found to be more potent both as regards HIV-1 EC~50~ (see [Table 3](#tbl3){ref-type="table"}) and in terms of maximal viral inhibition, which was seen to reach \>95% inhibition with sanglifehrin analogs including BC544 and NVP018 but only 60% with CsA and ALV. These data were similar when repeated in Jurkat cells, activated CD4+ peripheral blood T lymphocytes, and macrophages. One of the concerns with development of ALV for the treatment of HIV-1 was the presence of natural isolates with the H86Q ALV-resistant genotype ([@bib39]). NVP018 was tested against both laboratory-generated and natural H86Q isolates, and was found to be active in both cases.

NVP018 Is a Potent Inhibitor of HIV-1 Replication In Vivo {#sec2.8}
---------------------------------------------------------

As NVP018 had shown both potent in vitro HIV-1 inhibition and oral bioavailability, its effect on HIV-1 viral replication in the SCID-hu Thy/Liv mouse model was assessed. This model has been well validated against other standard HIV therapies and is thought to be a highly reproducible model with relevance to clinical effect ([@bib46]).

To enable comparison with data from previous studies with approved agents in the model, NVP018 or ALV was dosed orally bidaily for 14 days, starting 1 day before inoculation with the NL4.3 virus, at 50 mg/kg/day or 100 mg/kg/day.

Administration of NVP018 gave \>6 log~10~ reductions in HIV-1 RNA, and was more potent than ALV at protecting thymocytes and in reducing HIV-1 RNA and p24 levels at all concentrations tested (see [Figure 3](#fig3){ref-type="fig"} ). No overt signs of toxicity were seen in any of the mice at any dose level. The potency of NVP018 compares well with data previously published by [@bib46], as the \>6 log~10~ HIV-1 RNA log drop seen following NVP018 dosing was more pronounced than for approved therapies such as efavirenz, atazanavir, emtricitabine, and nevirapine, which showed 1--4 log~10~ viral RNA reductions after 21 days' bidaily dosing at 100 mg/kg.Figure 3Comparison of Implant P24 Levels, T lymphocytes, and HIV-1 RNA in the SCID-hu Thy/Liv Mouse Model, Following Bidaily Doses of Either 50 or 100 mg/kg Alisporivir (ALV) or NVP018 for 2 Weeks^∗^p ≤ 0.05 compared with untreated mice. Values represent the average concentrations/numbers calculated in a group of 6 mice with standard deviation shown with error bars.

Discussion {#sec3}
==========

The cyclophilin inhibitor NVP018 was generated using a combination of semisynthetic and bioengineering methods. These are frequently used independently, but in the past have been less commonly used together ([@bib27], [@bib12]). This enabled a combinatorial approach to NP drug discovery and led to the selection of NVP018, a compound with more potent cyclophilin inhibition, antiviral potency versus HBV, HCV, and HIV-1, and reduced off-target transporter inhibition compared with the parent compound, sanglifehrin A. A fluorine was introduced into the compound by mutasynthesis, a method that has been successful in introducing this substitution pattern in a less invasive way than semisynthetic chemistry ([@bib49], [@bib18], [@bib16], [@bib29], [@bib1]).

Second-generation cyclophilin inhibitors, such as NVP018, have the potential for therapeutic application in a number of areas, in particular chronic viral infection. This is due to their potency, high barrier to resistance, activity on multiple steps of the viral life cycle, and oral bioavailability. It is also worth noting the recent publications suggesting that these compounds might also have additional impact on interferon regulatory factors, which have long been implicated in the escape of certain viruses, such as HCV and HIV, from the immune system ([@bib36], [@bib6]). While cyclophilin inhibitors do not exhibit inhibition of all viruses, they have been shown to have activity against a wide variety of both RNA viruses (e.g. coronaviruses, HIV, and HCV) and DNA viruses (human CMV, HBV, varicella zoster virus). It is therefore tempting to speculate that cyclophilin inhibitors may be a step in the direction of agents with broad antiviral activity ([@bib24]).

We also anticipate that in the era of rapid genome sequencing and gene synthesis, bioengineering applications will continue to become more amenable and offer a more flexible route to improve NPs with potent inhibition of cellular targets, but with less than optimum drug-like properties. We hope that in the future, bioengineering and semisynthesis will be used more frequently in combination to optimize NPs with an aim to select candidates for clinical development.

Significance {#sec4}
============

**Moss et al. describe the generation and preclinical analysis of a bacterial natural product with activity as a host targeted antiviral drug. This was achieved by a combination of biosynthetic engineering and semisynthetic chemistry -- bringing together the advantages of each method to more efficiently optimize a bacterially produced, genetically encoded natural product. The preclinical analysis reveals potent activity against HCV, HIV, and HBV and a significantly improved profile compared with both the parent natural product and the cyclosporin A (CsA) class of cyclophilin inhibitors, of which alisporivir was in phase 3 for treatment of chronic HCV infection**.

Experimental Procedures {#sec5}
=======================

Compounds {#sec5.1}
---------

BC544 was synthesized according to the method published by [@bib33] (compound 3o therein). Alisporivir (DEBIO-025/DEB025) was synthesized according to the method published in US6,927,208 from CsA (\>99%) purchased from LC Labs, Woburn, MA, USA.

Genetic Engineering of *Streptomyces* sp. A92-308110 {#sec5.2}
----------------------------------------------------

In-frame deletion of the *sfaA* gene, coding for the tyrosine hydroxylase, was carried out using double recombination. The recombinant strain generated, BIOT-4585, could then be fed (*S*)-methyl 2-amino-3-(3-fluoro-5-hydroxyphenyl)propanoate hydrochloride salt and grown under appropriate fermentation conditions to generate BC457. Further details are available in the [Supplementary Information](#app2){ref-type="sec"}.

Semisynthesis of NVP018 from BC457 {#sec5.3}
----------------------------------

NVP018 was synthesized in three steps from BC457 using the same protocol as for compound BC544. In brief, BC457 was treated via modified Sharpless dihydroxylation conditions to form a diol, which was subsequently cleaved to generate an allylic aldehyde by the action of sodium periodate. Finally, the resultant allylic aldehyde was coupled with a suitable amide under Horner-Wadsworth-Emmons coupling conditions.

ADME Compound Analysis {#sec5.4}
----------------------

Solubility analysis, plasma protein binding, intravenous and oral pharmacokinetics, and toxicology were carried out using standard methods at Shanghai Chempartner, Shanghai, and efflux assays were carried out at Solvo Biotechnology, Hungary or Cyprotex, UK. Further details are available in the [Supplementary Information](#app2){ref-type="sec"}.

ELISA Analysis of CypA-NS5A Interactions {#sec5.5}
----------------------------------------

Test articles were tested for their capacities to block the interaction between CypA and HCV NS5A by ELISA. Specifically, we produced and purified recombinant glutathione *S*-transferase (GST), GST-CypA, and Con1 NS5A-His proteins and conducted ELISA. Nunc MaxiSorb eight-well strip plates were coated with GST or GST-CypA for 16 hr at 4°C and blocked. Recombinant NS5A-His (1 ng/ml) was added to wells in 50 μl of binding buffer (20 mM Tris \[pH 7.9\], 0.5 M NaCl, 10% glycerol, 10 mM DTT, and 1% NP-40) for 16 hr at 4°C. Captured NS5A-His was subsequently detected using mouse anti-His antibodies (1 μg/ml) (anti-6xHis, Clontech) and rabbit antimouse-horseradish peroxidase phosphatase (HRP) antibodies (1:1000 dilution). To test the effect of test articles on the CypA-NS5A complex formation, increasing concentrations of each test article were added to GST-CypA together with recombinant NS5A. All experiments were conducted twice. Data are presented in triplicate (inhibitory concentration of 50% \[IC~50~\]).

PPIase Inhibition Analysis {#sec5.6}
--------------------------

The inhibition of the PPIase activity of CypA was used to compare the inhibitory potential of sanglifehrin derivatives as an indication of their binding affinity to CypA. The PPIase activity of recombinant CypA, produced by thrombin cleavage of GST-CypA, is determined by following the rate of hydrolysis of *N*-succinyl-Ala-Ala-Pro-Phe-*p*-nitroanilide by chymotrypsin. Chymotrypsin only hydrolyzes the *trans* form of the peptide, and hydrolysis of the *cis* form, the concentration of which is maximized by using a stock dissolved in trifluoroethanol containing 470 mM LiCl, is limited by the rate of *cis*-*trans* isomerization. CypA was equilibrated for 1 hr at 5°C with selected sanglifehrin derivatives using a drug concentration range from 0.1 to 20 nM. The reaction was started by addition of the peptide, and the change in absorbance was monitored spectrophotometrically at 10 data points per second. The blank rates of hydrolysis (in the absence of CypA) were subtracted from the rates in the presence of CypA. The initial rates of the enzymatic reaction were analyzed by first-order regression analysis of the time course of the change in absorbance. All sanglifehrin derivatives exhibited anti-PPIase activity that correlated well with their capacity to prevent CypA-NS5A interactions analyzed by ELISA or pulldown.

HCV Antiviral Assay Huh 5-2 {#sec5.7}
---------------------------

Anti-HCV assay in Huh 5-2 cells was performed by seeding 6.5 × 10³ cells per well in a tissue-culture-treated white 96-well view plate (Packard, Canberra, Canada) in Dulbecco's modified essential medium (DMEM) supplemented with 250 μg/ml G418. Following incubation for 24 hr at 37°C (5% CO~2~), medium was removed and 3-fold serial dilutions in complete DMEM (without G418) of the test compounds were added in a total volume of 100 μl. After 4 days of incubation at 37°C, cell culture medium was removed and luciferase activity was determined using the luciferase assay system (Promega, Leiden, the Netherlands); the luciferase signal was measured using a Safire2 (Tecan, Switzerland). Relative luminescence units were converted to percentage of untreated controls. The 50% effective concentration (EC~50~) was defined as the concentration of compound that reduced the luciferase signal by 50%.

Cytostatic Assay {#sec5.8}
----------------

For the assessment of the potential cytostatic effect of the evaluated inhibitor, cells were seeded at a density of 6.5 × 10^3^ cells per well of a 96-well plate in complete DMEM. Serial dilutions of the test compounds in complete DMEM were added 24 hr after seeding. Cells were allowed to proliferate for 3 days at 37°C, after which the cell number was determined by means of the (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2*H*-tetrazolium)/phenazinemethosulfate (MTS/PMS) method (Promega). The CC~50~ (value derived from the dose-response curve) represents the concentration at which the metabolic activity of the cells would be reduced to 50% of the metabolic activity of untreated cells. The selectivity index, indicating the therapeutic window of the compound, was calculated as the CC~50~/EC~50~.

HCV Replicon Antiviral Assays {#sec5.9}
-----------------------------

The replicon cells (subgenomic replicons of genotype 1a \[H77\], 1b \[Huh7\], and 2a \[JFH-1\]) were grown in DMEM, 10% fetal bovine serum (FBS), 1% penicillin-streptomycin (pen-strep), 1% glutamine, 1% nonessential amino acids, and 250 μg/ml G418 in a 5% CO~2~ incubator at 37°C. All cell culture reagents were purchased from Mediatech (Herndon, VA). The replicon cells were trypsinized and seeded at 5 × 10^3^ cells per well in 96-well plates with the above media without G418. On the following day, the culture medium was replaced with DMEM containing compounds serially diluted in the presence of 5% FBS. The cells containing the HCV replicon were seeded into 96-well plates and test articles were serially diluted with DMEM plus 5% FBS. The diluted compound was then applied to appropriate wells in the plate. After 72 hr of incubation at 37°C, the cells were processed. The intracellular RNA from each well was extracted with an RNeasy 96 kit (Qiagen). The level of HCV RNA was determined by a real-time RT-PCR assay using TaqMan One-Step RT-PCR Master Mix Reagents (Applied Biosystems, Foster City, CA) and an ABI Prism 7900 sequence detection system (Applied Biosystems). The cytotoxic effects were measured with TaqMan Ribosomal RNA Control Reagents (Applied Biosystems) as an indication of cell numbers. The amount of the HCV RNA and rRNA were then used to derive applicable EC~50~ values (concentration that would inhibit the replicon replication by 50%).

In Vitro Assays for Assessment of HBV Antiviral Activity {#sec5.10}
--------------------------------------------------------

HepG2 cells stably replicating robustly HBV were treated with DMSO, tenofovir, BC544, NVP018, and ALV at three concentrations (0.1, 1, and 10 μM). Effect on HBV replication was monitored by treating HepG2 cells with test article at the relevant concentration for 3 days, removing the supernatant, retreating, and analyzing after an additional 72 hr by HBsAg ELISA, HBeAg ELISA, and HBV DNA in triplicate in cell extracts. These data were used to generate test/control values, which were plotted against the test article concentration and used to calculate IC~50~ values.

Huh7 cells were transfected with HBV DNA (8 μg) in the presence of DMSO, tenofovir, BC544, NVP018, and ALV at 2 μM. After day 3, amounts of de novo HBsAg protein present in cell extracts or supernatants were quantified by ELISA in triplicate. This was used to calculate a test/control value.

In Vitro Assay for Assessment of HIV Antiviral Activity {#sec5.11}
-------------------------------------------------------

Antiviral efficacy against HIV may be tested as follows. Blood-derived CD4+ T lymphocytes and macrophages were isolated as described previously ([@bib5]). In brief, human peripheral blood mononuclear cells (PBMCs) were purified from fresh blood by banding on Ficoll-Hypaque (30 min, 800 *g*, 25°C). Primary human CD4+ T cells were purified from PBMCs by positive selection with anti-CD4 Dynabeads and subsequent release using Detachabead. Cells were cultured in RPMI medium 1640 (Invitrogen) supplemented with 10% FCS, MEM amino acids, [l]{.smallcaps}-glutamine, MEM vitamins, sodium pyruvate, and penicillin plus streptomycin, and were subsequently activated with bacterial superantigen staphylococcal enterotoxin B (SEB; 100 ng/ml) and mitomycin C-killed PBMCs from another donor (10:1 PBMC:CD4 cell ratio). Three days after stimulation, cells were split 1:2 in medium containing interleukin-2 (IL-2) (200 units/ml final concentration). Cultures were then split 1:2 every 2 days in IL-2 medium and infected with HIV at 7 days after stimulation. For generating primary human macrophages, monocytes were purified from human PBMCs by negative selection and activated and cultured at a cell concentration of 10^6^/ml in DMEM, supplemented with 10% FCS, MEM amino acids, [l]{.smallcaps}-glutamine, MEM vitamins, sodium pyruvate, and penicillin (100 units/ml), streptomycin (100 mg/ml), and 50 ng/ml recombinant human granulocyte--macrophage colony-stimulating factor (GM-CSF), and maintained at 37°C in a humidified atmosphere supplemented with 5% CO~2~. To obtain monocyte-derived macrophages, cells were allowed to adhere to plastic and cultured for 6 days to allow differentiation.

CD4+ HeLa cells, Jurkat cells, activated CD4+ peripheral blood T lymphocytes, and macrophages (500,000 cells/100 μl) were incubated with pNL4.3-GFP (X4 virus) or pNL4.3-BaL-GFP (R5 virus) (100 ng of p24) in the presence of increasing concentrations of test article; 48 hr later, infection was scored by analyzing the percentage of GFP-positive cells by FACS and the EC~50~ calculated.

SCID-hu Thy/Liv Mouse Model {#sec5.12}
---------------------------

Stocks of NL4-3 (X4 virus) were prepared by transfection of 293T cells and collection of supernatants on day 2. Supernatants were filtered, aliquoted, and frozen at −80°C until use. Amounts of virus were quantified by p24 ELISA and infectivity of viral stocks verified using CD4+ HeLa-β-galactosidase reporter cells.

Human fetal thymus and liver were obtained from Advanced Bioscience Resources in accordance with federal, state, and local regulations. Coimplantation of thymus and liver fragments under the kidney capsule to create SCID-hu Thy/Liv mice and inoculation of the Thy/Liv implants with HIV-1 (1000 TCID50 HIV-1 per Thy/Liv implant by direct injection) were carried out as described ([@bib42], [@bib34]). Male C.B-17 SCID (model \#CB17SC-M, homozygous, C.B-Igh-1b/IcrTac-Prkdcscid) mice were obtained at 6--8 weeks of age from Taconic, and cohorts of 50--60 SCID-hu Thy/Liv mice were implanted with tissues from a single donor. Implants were inoculated 18 weeks after implantation with 50 μl of stock virus or complete DMEM (control infection) by direct injection. Animal protocols were approved by the TSRI Institutional Animal Care and Use Committee. Groups of six mice each were treated with NVP018 or ALV at 50 or 100 mg/kg/day by twice-daily oral gavage until implant collection 2 weeks after inoculation.

Implants were dispersed through nylon mesh into single-cell suspensions and assessed for p24 by ELISA (p24 \[ELISA\]: intracellular Gag pg/10^6^ cells), for viral RNA (bDNA assay: copies/10^6^ cells), and for depletion of thymocyte subsets by flow cytometry (% of CD3, CD4, CD8) as described previously ([@bib46], [@bib42], [@bib45]). Specifically, implant cells were stained with phycoerythrin cyanine dye CY7-conjugated anti-CD4 (BD Biosciences), phycoerythrin cyanine CY5.5-conjugated anti-CD8 (Caltag), allophycocyanin cyanine CY7-conjugated anti-CD3 (eBiosciences), and phycoerythrin-conjugated anti-W6/32 (DakoCytomation). Cells were fixed and permeabilized with 1.2% paraformaldehyde and 0.5% Tween 20, stained with fluorescein isothiocyanate-conjugated anti-p24 (Beckman Coulter), and analyzed on an LSR II (BD Biosciences). After collecting 100,000 total cell events, percentages of marker-positive (CD4+, CD8+, and CD4+CD8+) thymocytes in the implant samples were determined by first gating on a live lymphoid cell population identified by forward- and side-scatter characteristics and then by CD3 expression. Total RNA was extracted from frozen thymocyte pellets using Trizol LS (Invitrogen) and resuspended in nuclease-free water. The capsid region of the HIV-1 gag was amplified by RT-PCR using 10 μl of purified RNA and AmpliTaq Gold (Applied Biosystems) according to the manufacturer's instructions.
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[^1]: HBV data shows IC~50~ of HepG2 cells stably replicating HBV following treatment with DMSO, tenofovir, BC544, NVP018, and alisporivir, and test/control (T/C) value after 3 days of Huh7 cells following transfection with HBV DNA in the presence of DMSO, tenofovir, BC544, NVP018, and alisporivir at 2 μM.
